Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportas, R Kasmieh… - Proceedings of the …, 2009 - National Acad Sciences
The poor prognosis of patients with aggressive and invasive cancers combined with toxic
effects and short half-life of currently available treatments necessitate development of more …
effects and short half-life of currently available treatments necessitate development of more …
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportas, R Kasmieh… - Proceedings of the …, 2009 - pubmed.ncbi.nlm.nih.gov
The poor prognosis of patients with aggressive and invasive cancers combined with toxic
effects and short half-life of currently available treatments necessitate development of more …
effects and short half-life of currently available treatments necessitate development of more …
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportas, R Kasmieh, H Wakimoto… - Proceedings of the …, 2009 - cir.nii.ac.jp
抄録< jats: p> The poor prognosis of patients with aggressive and invasive cancers
combined with toxic effects and short half-life of currently available treatments necessitate …
combined with toxic effects and short half-life of currently available treatments necessitate …
[PDF][PDF] Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportasa, R Kasmieha, H Wakimotoc… - PNAS, 2009 - researchgate.net
Results Human mesenchymal stem cells (Fig. 1A) were efficiently transduced with our
recently engineered lentiviral vector (LV) constructs encoding firefly luciferase (Fluc) and …
recently engineered lentiviral vector (LV) constructs encoding firefly luciferase (Fluc) and …
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportas, R Kasmieh, H Wakimoto… - Proceedings of the …, 2009 - ui.adsabs.harvard.edu
The poor prognosis of patients with aggressive and invasive cancers combined with toxic
effects and short half-life of currently available treatments necessitate development of more …
effects and short half-life of currently available treatments necessitate development of more …
[PDF][PDF] Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportasa, R Kasmieha, H Wakimotoc… - PNAS, 2009 - academia.edu
Results Human mesenchymal stem cells (Fig. 1A) were efficiently transduced with our
recently engineered lentiviral vector (LV) constructs encoding firefly luciferase (Fluc) and …
recently engineered lentiviral vector (LV) constructs encoding firefly luciferase (Fluc) and …
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.
LS Sasportas, R Kasmieh, H Wakimoto… - Proceedings of the …, 2009 - europepmc.org
The poor prognosis of patients with aggressive and invasive cancers combined with toxic
effects and short half-life of currently available treatments necessitate development of more …
effects and short half-life of currently available treatments necessitate development of more …
Assessment of Therapeutic Efficacy and Fate of Engineered Human Mesenchymal Stem Cells for Cancer Therapy
LS Sasportas, R Kasmieh, H Wakimoto… - Proceedings of the …, 2009 - JSTOR
The poor prognosis of patients with aggressive and invasive cancers combined with toxic
effects and short half-life of currently available treatments necessitate development of more …
effects and short half-life of currently available treatments necessitate development of more …
[HTML][HTML] Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportas, R Kasmieh, H Wakimoto… - Proceedings of the …, 2009 - ncbi.nlm.nih.gov
The poor prognosis of patients with aggressive and invasive cancers combined with toxic
effects and short half-life of currently available treatments necessitate development of more …
effects and short half-life of currently available treatments necessitate development of more …
[PDF][PDF] Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy
LS Sasportasa, R Kasmieha, H Wakimotoc… - PNAS, 2009 - academia.edu
Results Human mesenchymal stem cells (Fig. 1A) were efficiently transduced with our
recently engineered lentiviral vector (LV) constructs encoding firefly luciferase (Fluc) and …
recently engineered lentiviral vector (LV) constructs encoding firefly luciferase (Fluc) and …